We report that mutation of specific residues in the human B 2 bradykinin (BK) receptor induces its marked constitutive activation, evaluated through inositol phosphate production in COS-7 cells expressing the wild-type or mutant receptors. We provide evidence for a strikingly high constitutive activation of the B 2 receptor induced by alanine substitution of the Asn 113 residue, located in the third transmembrane domain. These results are reminiscent of our previous finding that mutation of the homologous Asn 111 residue induces constitutive activation of the AT 1 angiotensin II receptor. BK overstimulation of the constitutively activated mutant N113A receptor was also observed. Phe replacement of the Trp 256 residue, fairly conserved in transmembrane domain VI of G protein-coupled receptors, also induced a less prominent but significant constitutive activation. Interestingly, the peptidic HOE 140 compound and an original nonpeptidic compound LF 16 0335, which both behaved as inverse agonists of the wild-type receptor expressed in COS-7 cells, became potent and efficient agonists of the two constitutively activated mutant N113A and W256F receptors. These parallel changes observed for two chemically unrelated series can serve as a basis for future studies of structurefunction relationships and modeling of activation processes, based on a detailed analysis of the network of helix-helix interactions, which stabilize the inactive receptor conformation and undergo rearrangements on transition to activated states.
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Kinins are biologically active peptides derived from large precursors (kininogens) through the action of serine proteases named kallikreins (Regoli and Barabé, 1980) . They produce a number of biological effects, including activation of sensory pain fibers, smooth muscle contraction, endotheliumdependent vasodilatation, and plasma extravasation (Regoli and Barabé, 1980; Proud and Kaplan, 1988; Dray and Perkins, 1993) . Kinin-induced responses are mediated by the activation of B 1 or B 2 receptors, which belong to the family of G proteincoupled receptors (GPCRs). Most of the physiological effects appear to be mediated by the activation of B 2 receptors that bind bradykinin (BK) and kallidin (Lys-bradykinin) with high affinities, with the corresponding carboxyl-terminal des-Arg metabolites being agonists of the B 1 receptor.
A number of mutagenesis or biochemical studies on the BK B 2 receptor (Kyle et al., 1994; Nardone and Hogan, 1994; AbdAlla et al., 1996; Jarnagin et al., 1996; Leeb et al., 1997; Fathy et al., 1998 , and herein cited references) have been paralleled by sustained efforts to provide molecular models of BK-receptor interactions (Kyle et al., 1994; Jarnagin et al., 1996; Leeb et al., 1997; Fathy et al., 1998) . The purpose of the present work was to complete these studies with mechanistic considerations about the receptor conformational changes that underlie the transitions from inactive to active receptor conformations. In this respect, the widely documented phenomena of constitutive activation of GPCR induced by appropriate point mutations (Cohen et al., 1992; Lefkowitz et al., 1993; Noda et al., 1996; Scheer et al., 1996; Groblewski et al., 1997) are useful to predict elements of the network of intramolecular interactions that stabilize the inactive receptor conformation and undergo rearrangements on activation. The finding of B 2 receptor-activating mutations reported in the present work took benefit of previous data from our laboratory relative to the process of activation of the type 1 angiotensin II (AT 1 ) receptor and the identity in amino acid sequences of the two receptors (about 30%, a high value in the subfamily of peptide hormone GPCR). (Joseph et al., 1995) . According to this model, the inactive receptor conformation would involve interaction between Asn 111 and Tyr 292 , that is, hormone stimulation would facilitate the disruption of this interaction and allow Tyr 292 to interact with the conserved Asp 74 , which was previously shown to be essential for receptor coupling to phospholipase C (Bihoreau et al., 1993) . Experimental support to this hypothesis was the finding that Tyr 292 3 Phe mutation severely impaired inositol phosphate production induced by angiotensin II (Marie et al., 1994) and that Asn 111 3 Ala mutation led to constitutive activation of the receptor (Groblewski et al., 1997 Hess et al., 1992) . Our goal was to check whether these residues might play a role in the B 2 receptor activation, as previously found by other authors for the conserved Asp residue in the rat receptor . This comparative study provides a good opportunity to tackle the problem of conservation of molecular events underlying the activation process. The main finding of the present study was the striking constitutive activation of the B 2 receptor induced by mutation of Asn 113 in TM III. We also found constitutive activation of the B 2 receptor mutated at its Trp 256 residue in TM VI. Moreover, the constitutively activated mutant (CAM) receptors displayed striking changes in their pharmacological properties: they were overstimulated by peptidic and a nonpeptidic compounds that behaved as inverse agonists of the wild-type (WT) receptor. (Pruneau et al., 1998) . COS-7 cells were from the European Cell Type Collection (Salisbury, UK).
Materials and Methods

Reagents and Ligands
Site-Directed Mutagenesis and Receptor Expression
The WT receptor and all mutated receptors were tagged through the addition of a 10-amino-acid epitope from the c-myc oncogene at the N termini of receptors truncated at the Asn 3 residue. The cDNA constructs included a Kozak sequence. The various mutations were carried out as described previously (Marie et al., 1994; Groblewski et al., 1997) . The WT or mutant receptors were subcloned in the EcoRI and XbaI sites of the eukaryotic expression vector pCMV polylinker. Receptors were transiently expressed in COS-7 cells by using the electroporation transfection method: 10 7 cells were resuspended in 300 l of electroporation buffer (50 mM K 2 HPO 4 , 20 mM KOH, 20 mM CH 3 COOK, and 27 mM MgSO 4 , pH 7.40) and incubated for 10 min at room temperature in an electroporation cuvette (0.4-cm electrode gap; BioRad, Hercules, CA) with 20 g of pCMV carrier and different amounts of pCMV containing cDNA receptor sequences (2.5-100-ng range). They were submitted to an electric discharge (950 F, 280 V, 50 ms) and then cultured for 2 days at 37°C in Dulbecco's modified Eagle's medium, 4.5 g/liter glucose, 10% fetal calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin before binding or inositol phosphate (IP) accumulation experiments.
Several amounts of pCMV-containing cDNA receptor sequences were systematically used for transfection to compare the properties of receptors expressed at similar levels in the same experiment, a condition required to accurately evaluate constitutive activation phenomena.
Routine evaluation of binding site numbers was carried out using 5 nM [
3 H]BK in the presence or absence of an excess of unlabeled BK (1 M).
Binding Assays
Plasma Membrane. Crude membranes from COS-7 cells transiently expressing the WT or mutant B 2 receptors were prepared as described previously (Marie et al., 1994) . 5 cells/well) was carried out at 4°C in Dulbecco's phosphate-buffered saline supplemented with 140 g/ml bacitracin, 1 mg/ml bovine serum albumin, 1 mM o-phenanthroline, and 10 Ϫ5 M captopril, pH 7.0, using a 3-h incubation time, under gentle agitation. Bound radioactivity was evaluated after washing the cells twice with cold binding medium and collecting them in 500 l of 0.1 N NaOH.
IP Assays
COS-7 cells expressing the WT or mutant receptors were grown in 6-well tissue culture clusters and labeled for 24 h with myo-[2-3 H]inositol (1.5 ml/well, 1 Ci/ml) in medium 199 deprived of serum. Before stimulation, cells were incubated at 37°C for 1 h in IP buffer [consisting of 116 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 5 mM NaHCO 3 , 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 11 mM glucose, 140 g/ml bacitracin, and 10 Ϫ5 M captopril, pH 7.4]. After a 15-min preincubation in medium containing 10 mM LiCl, cells were incubated in the presence or absence of ligands for 15 min at 37°C in medium containing 10 mM LiCl. Pooled IPs were extracted and measured as described previously (Paquet et al., 1990) . The preincubation step was omitted in the experiments designed to evaluate the properties of HOE 140 and LF 16 0335.
Results and Discussion
To assess the expression of the WT or mutated B 2 receptors and to facilitate their purification, a c-myc epitope (10 amino acids) was fused with receptors truncated at the Asn 3 glycosylation site. This modification had no significant influence on the pharmacological properties of the receptors, as as- 50 values for BK-induced IP production (0.48 Ϯ 0.25 nM and 0.51Ϯ 0.27 nM for WT and tagged receptors, respectively). The suppression of the potential glycosylation site located near the N terminus, already applied to the AT 1 (J. Marie, unpublished results), might favor tag recognition by a specific antibody. In all described experimental data, "WT receptor" refers to the tagged receptor.
Role of Asn 76 and Tyr 295 in B 2 Receptor Activation
Properties of the D76N Mutant B 2 Receptor. The conserved Asp 76 residue of the human B 2 receptor, which is located in TM II and essential for signal transduction in many GPCR, including the AT 1 receptor (Bihoreau et al., 1993) , was mutated into Asn, as in a previous study of the rat B 2 receptor . The binding affinity of 1 and 2) . Nevertheless, the residual PLC coupling activity (55%) was surprisingly high if one considers the role generally found for the charged Asp residue. In particular, when carried out in the AT 1 receptor, the Asp 3 Asn mutation led to either complete (Bihoreau et al., 1993) or almost complete (unpublished results of our laboratory) suppression of phospholipase C (PLC) coupling activity. The dose-response curves relative to BK stimulation (Fig. 2) revealed that Asp 3 Asn replacement does not modify the EC 50 value. This partial reduction in PLC coupling is in agreement with recent results relative to the D78N rat B 2 receptor . However, at variance with this latter work, we could not find any significant constitutive activation of the D76N mutant human receptor (Fig. 2) . It cannot be excluded that species differences in receptor sequences are responsible for these discrepancies. Mutation of Asp 76 to Ala further decreased the maximal BK stimulation of IP production (residual activity, 31%) and slightly increased the EC 50 value (Fig. 2) . Nevertheless, the D76A mutant receptor was not constitutively activated, thus confirming that hydrogen bonding involving a residue at position 76 probably is not essential for the stabilization of the inactive receptor conformation. Role of Na ؉ Ions. The following considerations led us to perform a preliminary analysis of the role of Na ϩ ions on BK recognition by the WT or mutated human B 2 receptors and receptor coupling to PLC: 1) the well-documented ability of these ions to modulate the GTP effect on receptor-G protein interactions, which usually requires the negative charge of the conserved aspartate in TM II (Kong et al., 1993; Ceresa and Limbird, 1994) ; 2) the recent work reporting constitutive activation of the rat B 2 receptor when Na ϩ concentration was decreased and proposing that the sodium salt of Asp 78 corresponds to a very low affinity state for BK, whereas the high-affinity state corresponds to the free aspartate; and 3) our previous finding that the affinity of angiotensin II for the CAM N111A AT 1 receptor was insensitive to Na ϩ ion-plus-GTP␥S treatment (Groblewski et al., 1997) , as a result of profoundly modified coupling properties.
Membranes from COS-7 cells expressing the WT receptor displayed high-affinity binding sites (K d ϭ 0.47 nM, B max ϭ 0.49 pmol/mg; Table 1) . Properties of the Y295F Mutant B 2 Receptor. Because the mutation of Tyr 292 in the AT 1 receptor drastically reduced receptor coupling to PLC (Marie et al., 1994) , we checked whether the homologous Tyr 295 , located in TM VII of the human B 2 receptor, could be involved in its activation process. The Tyr 3 Phe mutation had no incidence on the receptor affinity for BK (Table 1) . Moreover, the receptor coupling to PLC was not significantly affected, as assessed by the unchanged ability of BK to stimulate IP production in COS-7 cells (Fig. 1) . This finding constitutes a striking difference between the B 2 and AT 1 receptors (Groblewski et al., unpublished results) , indicating that some events associated to their activation processes are not conserved.
Constitutive Activation of the B 2 Receptor Induced by Asn 113 and Trp 256 Mutation
Constitutive Activation of the N113A B 2 Receptor. The Asn 113 residue of the human B 2 receptor, located in its third TM, was replaced by alanine. The WT and N113A mutant receptors were expressed at various levels in COS-7 cells and their coupling to PLC, measured as IP accumulation. The N113A receptor displayed an exceptionally high constitutive activation (up to 40-fold increase in basal activity compared with the WT receptor). Figure 3 shows the basal and BK-stimulated responses of the WT and mutant receptors as a function of their expression levels. The basal activity of the N113A receptor was higher than the maximal BKstimulated activity of the WT receptor. The mutant receptor could be further activated by ϳ1.5-fold by saturating doses of BK (Figs. 3 and 4) , with a slight increase in the EC 50 value relative to BK stimulation (0.86 nM versus 0.19 nM for WT, in the typical experiment reported in Fig. 4 ). 256 was mutated to phenylalanine or glutamine to preserve the aromatic character of tryptophane or its ability to participate in hydrogen bonding. These mutations did not affect the binding of BK (Table 1) . A 3-to 4-fold (up to 10-fold in some experiments) enhancement of basal IP production was reproducibly found for the W256F and W256Q mutants compared with the WT , and D76A mutant B 2 receptors. The WT and D76N receptors were transiently expressed at comparable levels (1.05 ϫ 10 5 and 1.22 ϫ 10 5 sites/cell, respectively) in COS-7 cells. The stimulation of IP production by varying doses of BK was evaluated as described in Materials and Methods. The EC 50 values were 1.5, 1.6, and 2.5 nM for the WT, D76N, and D76A receptors, respectively, and the maximal BK stimulations of the mutant receptors represented 53% and 25% of that WT receptor. The reported typical experiment is representative of three independent comparative experiments performed in triplicate (mean Ϯ S.D. EC 50 values ϭ 1.2 Ϯ 0.3, 1.5 Ϯ 0.6, and 2.9 Ϯ 0.9 nM for the WT, D76N, and D76A receptors, respectively; maximal BK stimulations of the asparagine and alanine mutant receptors represented 55 Ϯ 2% and 31 Ϯ 6% of that of the WT receptor)
Constitutive Activation of the Human B 2 Bradykinin Receptor 95 receptor expressed at similar expression levels in COS-7 cells, within the same experiment (Fig. 1) . The IP response to BK was also increased for the mutated receptors (Fig. 1 The similar properties of the W256F and W256Q mutant B 2 receptors deserve a comment: the inability of the Trp 3 Gln mutation to restore a WT constrained conformation could be explained by a spatial localization inadequate for its participation in hydrogen bonding. Refined receptor models, associated to a more systematic mutagenesis scanning at positions 113 and 256, would be required for the interpretation of subtle differences between amino acid side chain orientations in the WT and mutated receptors.
Pharmacological Properties of HOE 140 and the Nonpeptide LF 13 0335 for the WT and CAM Receptors. HOE 140 was originally described as a B 2 -specific receptor antagonist (Wirth et al., 1991) . Taking into account the inverse agonist properties of this compound for the native B 2 receptor from rat myometrium smooth muscle (Leeb-Lundberg et al., 1994) and its agonist properties on the recombinant rat B 2 receptor expressed in COS cells , we evaluated its ability to modulate IP production in cells transfected with the human WT and the N113A or W256F mutant receptors. In some experiments, we found a basal activity of the WT receptor much higher than that of control untransfected cells. In such situations, we found a strong inverse agonism behavior of HOE140 on the WT receptor, characterized by an almost complete inhibition of the basal activity, with an EC 50 value of about 2 nM (Fig. 5) . On the other hand, HOE 140 was a potent and efficient agonist of the N113A and W256F mutants; its intrinsic activity was 70 to 90% of that of BK, with EC 50 values in the range of 2 to 3 nM (Fig. 5) .
Interestingly, quite similar properties were found for LF16 0335 (see chemical structure in Fig. 6A ), a novel potent and selective nonpeptide antagonist of the human B 2 receptor (Pruneau et al., 1998) . LF 16 0335 acted as an inverse agonist of the WT receptor (Fig. 6B) and as an agonist of the N113A and W256F CAM receptors (Fig. 6, C and D) .
The parallel pharmacological behavior of both CAM receptors provides evidence that their activated states share sufficient structural analogies to be both stabilized (or induced) through their interaction with HOE 140 and the nonpeptide derivative LF16 0335.
The properties of the N113A and W256F human B 2 receptors can be tentatively interpreted in the light of the allosteric ternary complex model proposed by Lefkowitz et al. (1993) and refined by Kenakin (1995) . According to this model, the strong constitutive activity of the N113A receptor and, to a lesser extent, of the W256F mutant might indicate that the transition from R to R* was facilitated through the suppression of a structural constraint involving the interactions of Asn 113 or Trp 256 with other residues located on neighboring transmembrane helices or, as an interesting possibility, a direct interaction between them. As a consequence of this loss of intramolecular interaction, the energy difference between R* and R would be much lower for the CAM receptor than for the WT receptor, so the ratio [R* CAM ]/[R CAM ] is likely to be much greater than [R* WT ]/[R WT ]. Such an interpretation has been previously provided for a constitutively activated beta-2 adrenergic receptor through the construc- (Gether et al., 1997a) .
Besides modifications of the constant of isomerization between R and R* and the affinity of R* for the G protein, a point mutation can sometimes induce marked changes in the pharmacological properties of ligands (agonism, antagonism, inverse agonism) (Noda et al., 1996; Groblewski et al., 1997) , so parameters accounting for the pattern of a given ligand (Lefkowitz et al., 1993; Kenakin, 1995) are obviously modified on mutation. This might explain the lack of important changes in EC 50 values relative to BK-activated IP production and the affinities of [ 3 H]BK for the three mutants N113A, W256F, and W256Q compared with the WT receptor. In this respect, a possible loss of a direct interaction between a BK residue and Asn 113 or Trp 256 might compensate an affinity increase expected from constitutive activation (Lefkowitz et al., 1993) . The construction of a reliable docking of BK into the receptor is required to answer this question.
The experimental data relative to the changes in pharmacological properties of the CAM receptors are consistent with the following assumptions: 1) the inverse agonism properties of HOE 140 and LF 16 0335 for the WT receptor indicate that these compounds preferentially stabilize (or induce) the inactive conformation R WT , and 2) it is difficult to accurately predict structural differences between the activated states R* CAM and R* WT and the induction processes involved in the stabilization of R*-ligand complexes. Because HOE 140 and LF 16 0335 are agonists of the CAM receptors, they are expected to preferentially stabilize R* CAM conformations versus R CAM . These changes in pharmacological properties of WT and CAM receptors will be useful to explore structurefunction relationships integrating the preferential recognition and/or induction of receptor conformations by the various ligands.
Conclusion
The present study reports mutations in the human bradykinin B 2 receptor that markedly increase its constitutive activity. It was initiated by previous works from our laboratory on the AT 1 receptor (Marie et al., 1994; Joseph et al., 1995; Groblewski et al., 1997; Groblewski et al., unpublished results) assuming that the extent of amino acid conservation between the two receptors offers the opportunity to study the problem of the conservation of molecular events associated to their activation processes. Interestingly, mutation of Asn 111 to Ala led to a strong constitutive activation of the AT 1 receptor and to striking changes in the pharmacological properties of some peptidic ligands (Groblewski et al., 1997) . We investigated the possible role of its counterpart in the human B 2 receptor and found an exceptionally high constitutive activation on Asn 113 3 Ala mutation, characterized by up to 40-fold increases in hormone-independent receptor coupling to PLC and the ability of BK to overstimulate the mutated receptor. The K d for [
3 H]BK binding to the N113A receptor was unchanged, which is in agreement with data obtained for the rat receptor , and the BK-induced overstimulation was characterized by a moderately increased EC 50 value. One must mention that these results do not preclude the possibility of a direct interaction of BK with Asn 113 . Indeed, compensating variations of the thermodynamic parameters describing the allosteric ternary complex model can theoretically account for these observations, as already postulated for the interaction of Asn 111 of the AT 1 receptor with the Tyr 4 residue of the hormone (Joseph et al., 5 and 9.6 ϫ 10 4 sites/cell for the WT and the N113A mutant receptors, respectively. HOE 140 inverse agonism for the WT receptor and agonism for the N113A receptor were characterized by EC 50 values of 2.4 and 2.3 nM. respectively (mean Ϯ S.D. value for three separate experiments ϭ 2.3 Ϯ 0.8 and 2.7 Ϯ 0.5 nM for the WT and N113A receptors, respectively). The maximal overstimulation of the mutant receptor by HOE 140 was 88% of the effect of 1 M BK measured in the same experiment (mean value, 85 Ϯ 11%). The control IP production in nontransfected COS-7 cells represented 18% of the basal IP production by the WT receptor. B, comparison of the WT and W256F receptor properties: the mean expression levels in the described typical experiment measured through [ 3 H]BK binding were 3.0 ϫ 10 5 and 3.2 ϫ 10 5 sites/cell for the WT and the W256F mutant receptors, respectively. HOE 140 agonism for the W256F receptor was characterized by an EC 50 value of 2.3 nM (mean Ϯ S.D. value for three separate experiments ϭ 2.8 Ϯ 0.7 nM). The maximal overstimulation of the mutant receptor by HOE 140 was 75% of that induced by 1 M BK measured in the same experiment (mean value, 72 Ϯ 13%). 5 sites/cell) and W256F (6.2 ϫ 10 5 sites/cell): the maximal non-peptide-induced stimulations in the reported typical experiment were 98% and 76% of the BK-induced maximal stimulation, and the EC 50 values were about 0.1 and 1.8 nM, respectively. The mean Ϯ S.D. values for three separate experiments were EC 50 ϭ 0.26 Ϯ 0.11 nM and intrinsic activity ϭ 95 Ϯ 6% for the N113A mutant and EC 50 ϭ 1.6 Ϯ 0.2 nM and intrinsic activity ϭ 74 Ϯ 12% for the W256F mutant.
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Finally, the B 2 receptor, which displays an extreme conformational flexibility on mutation of its Asn 113 residue and spectacular changes in pharmacological properties on mutation of Asn 113 and Trp 256 , constitutes an example of choice for the future study of the dynamic aspect of interconversion between active and inactive conformations. The concomitant analysis of the B 2 and AT 1 receptors offers the opportunity to compare the activation processes of a subclass of peptide hormone receptors with those of rhodopsin or adrenergic receptors.
